



1632
JFW


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

August 30, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
August 30, 2004	
Date	Gina N. Shishima

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/017,472 entitled "METHODS OF TREATMENT INVOLVING HUMAN MDA-7" – Sunil Chada et al.*
Our reference: INGN:097US
UT reference: MDA01-091


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references C112-C125.

No fees are believed to be due in connection with the filing of this Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/ INGN:097US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Gina N. Shishima
Reg. No. 45,104

GNS/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Sunil Chada *et al.*

Serial No.: 10/017,472

Filed: December 7, 2001

For: METHODS OF TREATMENT
INVOLVING HUMAN MDA-7

Group Art Unit: 1632

Examiner: Qian J. Li

Atty. Dkt. No.: INGN:097US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

August 30, 2004

Date


Gina N. Shishima

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to

patentability as defined in 37 C.F.R. § 1.56(b). This application is related by inventorship to co-pending U.S. Patent application no. 10/791,692, filed March 2, 2004.

No fees are believed to be due in connection with the filing of this , however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INGN:097US.

Applicants respectfully request that the listed documents be placed in the file at this time and be made of record should prosecution in this case be re-opened.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: August 30, 2004

Form PTO-1449 (modified)

Atty. Docket No.

INGN:097US

Serial No.

10/017,472

List of Patents and Publications for Applicant's

Applicant

Sunil Chada *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

December 7, 2001

Group:

1632

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C112	Angiolillo <i>et al.</i> , "A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12," <i>Ann. NY Acad. Sci.</i> , 795:158-167, 1996.
	C113	Cao <i>et al.</i> , "Adenoviral transfer of mda-7 leads to BAX up-regulation and in mesothelioma cells, and is abrogated by over-expression of BCL-XL," <i>Molecular Medicine</i> , 8(12):869-876, 2002.
	C114	Caudell <i>et al.</i> , "The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24," <i>J. Immunol.</i> , 168:6041-6046, 2002.
	C115	Chen and Tan, "Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin," <i>Oncogene</i> , 17:173-178, 1998.
	C116	Ekmekcioglu <i>et al.</i> , "Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulated iNOS expression in melanoma cells," <i>Mol. Cancer Therapeutics</i> , 2:9-17, 2003.
	C117	Fathallah-Shaykh <i>et al.</i> , "Gene transfer of IFN- γ established brain tumors represses growth by antiangiogenesis," <i>J. Immunol.</i> , 164:217-222, 2000.
	C118	Kawabe <i>et al.</i> , "Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms," <i>Molecular Therapy</i> , 6(5):637-644, 2002.
	C119	Lebedeva <i>et al.</i> , "The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells," <i>Oncogene</i> , 21:708-718, 2002.

25443424.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
INGN:097USSerial No.
10/017,472

List of Patents and Publications for Applicant's

Applicant
Sunil Chada *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
December 7, 2001Group:
1632U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1***Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C120	Majumder <i>et al.</i> , "Regulation of human IP-10 gene expression in astrocytoma cells by inflammatory cytokines," <i>J. Neurosci. Res.</i> , 54:169-180, 1998.
	C121	Ramesh <i>et al.</i> , "Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector," <i>Molecular Therapy</i> , 3(3):337-350, 2001.
	C122	Ramesh <i>et al.</i> , "Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor," <i>Cancer Res.</i> , 63(16):5105-5113, 2003.
	C123	Russell <i>et al.</i> , "Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment," <i>Cancer Res.</i> , 59:5239-5244, 1999.
	C124	Saeki <i>et al.</i> , "Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo," <i>Oncogene</i> , 21:4558-4566, 2002.
	C125	Spitz <i>et al.</i> , "Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation," <i>Clinical Cancer Research</i> , 2:1665-1671, 1996.

25443424.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.